Urothelial Carcinoma
Conditions
Brief summary
This is a feasibility trial of anti-PDL1/PD1 (pembrolizumab) and stereotactic body radiation therapy (SBRT) in patients with advanced, platinum-refractory urothelial carcinoma.
Interventions
DRUGPembrolizumab
200 mg IV q 21 days
RADIATIONSBRT
Stereotactic body radiation therapy (SBRT) that will commence not later than the initiation of the second cycle of pembrolizumab. SBRT dose and fractionation will be at the discretion of the treating radiation oncologist, and will be selected to respect the normal tissue tolerance of adjacent organs at risk.
Sponsors
University of Michigan Rogel Cancer Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Subjects must have a histologic diagnosis of urothelial carcinoma * Subjects must have radiologic evidence of metastatic disease with measurable disease by RECIST 1.1 criteria other than the target lesion(s) for SBRT * Subjects must have at least 1 metastatic lesion previously not radiated that is amenable to SBRT per treating radiation oncologist. * Subjects must have had progression of disease within 12 months of platinum-containing chemotherapy (chemotherapy could have been given in the neoadjuvant, adjuvant or metastatic setting) for urothelial cancer * ECOG performance status of 0 to 2 (Eastern Cooperative Oncology Group Performance Status: an attempt to quantify cancer patients' general well-being and activities of daily life. The score ranges from 0 to 5 where 0 is asymptomatic and 5 is death.) * Absolute neutrophil count of ≥ 1000/mm3, platelet count ≥ 100,000/mm3, hemoglobin ≥ 8.0 g/dl; total bilirubin/ALT/AST \< 2.5 x upper limit of normal (patients with known gilbert disease who have serum bilirubin ≤3x ULN may be enrolled); serum creatinine \<3.0mg/dl or if elevated, a calculated estimated glomerular filtration rate (eGFR) of ≥30 mL/min/1.73 m2 * Subjects must have recovered to baseline or ≤ grade 1 CTCAE v 4.03 from toxicities related to any prior treatments unless AE(s) are clinically non-significant and/or stable on supportive therapy * Subjects must be ≥ 2 weeks from most recent systemic therapy or most recent radiation therapy * Women of childbearing potential must have a negative serum or urine pregnancy test within 28 days prior to registration. * Age ≥ 18 years
Exclusion criteria
* Prior treatment with anti-PD-1/PD-L1 and anti-CTLA-4 is NOT allowed. Prior intravesical BCG (Bacillus Calmette-Guerin) therapy is allowed * Treatment with any investigational agent or on an interventional clinical trial within 30 days prior to registration. * No prior or concurrent malignancy is allowed except for: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, localized or locally advanced prostate cancer definitively treated without recurrence or with biochemical recurrence only, or any other cancer fully treated or from which the subject has been disease-free for at least 2 years. * Autoimmune diseases such as rheumatoid arthritis are NOT allowed. Vitiligo, mild psoriasis (topical therapy only) or hypothyroidism are allowed * Need for systemic corticosteroids \>10mg prednisone daily or equivalent alternative steroid * Any history of organ allografts * Any history of HIV or hepatitis B infection * Known brain metastases
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The Percentage of Subjects Who Receive 4 Doses of Pembrolizumab and at Least One Session of Treatment of SBRT | 15 weeks | Feasibility will be determined by the percentage of subjects who receive 4 doses of pembrolizumab and at least one session of treatment of SBRT (Stereotactic Body Radiation Therapy) within 15 weeks from the first dose of pembrolizumab. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The Number of Grades 3-5 Drug Related Adverse Events (AEs) | 30 days post last dose | The number of grades 3-5 drug related adverse events (AEs) will be recorded. AEs will be graded using the CTCAE v4.03 |
| The Percentage of Patients That Respond to Treatment | 51 weeks (up to 17, 3 week doses) | The percentage of patients that achieve either a complete response (CR) or partial response (PR). Response will be reported separately using RECIST and irRECIST criteria. CR (RECIST): Disappearance of all target lesions, determined by two separate observations conducted not less than 4 weeks apart. There can be no appearance of new lesions CR (irRECIST): Disappearance of all lesions in two consecutive observations not less than 4 wk apart PR (RECIST): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. There can be no appearance of new lesions PR (irRECIST): ≥50% decrease in tumor burden compared with baseline in two observations at least 4 wk apart |
| Progression Free Survival (PFS) Time | 24 months | Progression-free survival (PFS) is defined as the duration of time from start of treatment to time of progressive disease (PD), or death, whichever occurs first, up to 24 months. PD (RECIST): At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started, or the appearance of one or more new lesions PD (irRECIST): At least 25% increase in tumor burden compared with nadir (at any single time point) in two consecutive observations at least 4 wk apart |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Pembrolizumab + SBRT Pembrolizumab: 200 mg IV q 21 days
SBRT: Stereotactic body radiation therapy (SBRT) that will commence not later than the initiation of the second cycle of pembrolizumab. SBRT dose and fractionation will be at the discretion of the treating radiation oncologist, and will be selected to respect the normal tissue tolerance of adjacent organs at risk. | 6 |
| Total | 6 |
Baseline characteristics
| Characteristic | Pembrolizumab + SBRT |
|---|---|
| Age, Continuous | 64 years STANDARD_DEVIATION 8 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 6 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 6 Participants |
| Region of Enrollment United States | 6 participants |
| Sex: Female, Male Female | 1 Participants |
| Sex: Female, Male Male | 5 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 3 / 6 |
| other Total, other adverse events | 6 / 6 |
| serious Total, serious adverse events | 1 / 6 |
Outcome results
Primary
The Percentage of Subjects Who Receive 4 Doses of Pembrolizumab and at Least One Session of Treatment of SBRT
Feasibility will be determined by the percentage of subjects who receive 4 doses of pembrolizumab and at least one session of treatment of SBRT (Stereotactic Body Radiation Therapy) within 15 weeks from the first dose of pembrolizumab.
Time frame: 15 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Pembrolizumab + SBRT | The Percentage of Subjects Who Receive 4 Doses of Pembrolizumab and at Least One Session of Treatment of SBRT | 83 percentage of participants |
Secondary
Progression Free Survival (PFS) Time
Progression-free survival (PFS) is defined as the duration of time from start of treatment to time of progressive disease (PD), or death, whichever occurs first, up to 24 months. PD (RECIST): At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started, or the appearance of one or more new lesions PD (irRECIST): At least 25% increase in tumor burden compared with nadir (at any single time point) in two consecutive observations at least 4 wk apart
Time frame: 24 months
Population: One patient who did not have non-radiated measurable disease is not included in the results table.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Pembrolizumab + SBRT | Progression Free Survival (PFS) Time | Patient 1 | 23 months |
| Pembrolizumab + SBRT | Progression Free Survival (PFS) Time | Patient 2 | 10 months |
| Pembrolizumab + SBRT | Progression Free Survival (PFS) Time | Patient 3 | 2 months |
| Pembrolizumab + SBRT | Progression Free Survival (PFS) Time | Patient 4 | NA months |
| Pembrolizumab + SBRT | Progression Free Survival (PFS) Time | Patient 5 | 6 months |
Secondary
The Number of Grades 3-5 Drug Related Adverse Events (AEs)
The number of grades 3-5 drug related adverse events (AEs) will be recorded. AEs will be graded using the CTCAE v4.03
Time frame: 30 days post last dose
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Pembrolizumab + SBRT | The Number of Grades 3-5 Drug Related Adverse Events (AEs) | 0 events |
Secondary
The Percentage of Patients That Respond to Treatment
The percentage of patients that achieve either a complete response (CR) or partial response (PR). Response will be reported separately using RECIST and irRECIST criteria. CR (RECIST): Disappearance of all target lesions, determined by two separate observations conducted not less than 4 weeks apart. There can be no appearance of new lesions CR (irRECIST): Disappearance of all lesions in two consecutive observations not less than 4 wk apart PR (RECIST): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. There can be no appearance of new lesions PR (irRECIST): ≥50% decrease in tumor burden compared with baseline in two observations at least 4 wk apart
Time frame: 51 weeks (up to 17, 3 week doses)
Population: One patient who did not have non-radiated measurable disease is not included.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Pembrolizumab + SBRT | The Percentage of Patients That Respond to Treatment | RECIST | 40 percentage of participants |
| Pembrolizumab + SBRT | The Percentage of Patients That Respond to Treatment | irRECIST | 40 percentage of participants |